Sumatriptan 3-Hydroxy-2-Oxo Impurity

Sumatriptan 3-Hydroxy-2-Oxo Impurity is a structurally related degradation byproduct of the parent drug Sumatriptan, characterized by the introduction of a hydroxyl group at the C3 position of the indoline ring and an oxo group at the C2 position of the pyridine moiety. These modifications disrupt the native sulfonamide pharmacophore while retaining the core indole scaffold. The compound arises via oxidative stress pathways, reflecting specific metabolic vulnerabilities in the parent molecule. This impurity serves as a critical HPLC reference standard for quantifying degradation products in Sumatriptan formulations.